The role of neuropathology in the management of patients with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline

Document Type

Article

Publication Date

12-1-2015

Publication Title

Journal of neuro-oncology

Abstract

TARGET POPULATION: Adult patients (age ≥18 years) who have suspected low-grade diffuse glioma.

QUESTION: What are the optimal neuropathological techniques to diagnose low-grade diffuse glioma in the adult?

RECOMMENDATION: LEVEL I: Histopathological analysis of a representative surgical sample of the lesion should be used to provide the diagnosis of low-grade diffuse glioma.

LEVEL III: Both frozen section and cytopathologic/smear evaluation should be used to aid the intra-operative assessment of low-grade diffuse glioma diagnosis. A resection specimen is preferred over a biopsy specimen, to minimize the potential for sampling error issues.

TARGET POPULATION: Patients with histologically-proven WHO grade II diffuse glioma.

QUESTION: In adult patients (age ≥18 years) with histologically-proven WHO grade II diffuse glioma, is testing for IDH1 mutation (R132H and/or others) warranted? If so, is there a preferred method?

LEVEL II: IDH gene mutation assessment, via IDH1 R132H antibody and/or IDH1/2 mutation hotspot sequencing, is highly-specific for low-grade diffuse glioma, and is recommended as an additional test for classification and prognosis.

TARGET POPULATION: Patients with histologically-proven WHO grade II diffuse glioma.

QUESTION: In adult patients (age ≥18 years) with histologically-proven WHO grade II diffuse glioma, is testing for 1p/19q loss warranted? If so, is there a preferred method?

LEVEL III: 1p/19q loss-of-heterozygosity testing, by FISH, array-CGH or PCR, is recommended as an additional test in oligodendroglial cases for prognosis and potential treatment planning.

TARGET POPULATION: Patients with histologically-proven WHO grade II diffuse glioma.

QUESTION: In adult patients (age ≥18 years) with histologically-proven WHO grade II diffuse glioma, is MGMT promoter methylation testing warranted? If so, is there a preferred method?

RECOMMENDATION: There is insufficient evidence to recommend methyl-guanine methyl-transferase (MGMT) promoter methylation testing as a routine for low-grade diffuse gliomas. It is recommended that patients be enrolled in properly designed clinical trials to assess the value of this and related markers for this target population.

TARGET POPULATION: Patients with histologically-proven WHO grade II diffuse glioma.

QUESTION: In adult patients (age ≥18 years) with histologically-proven WHO grade II diffuse glioma, is Ki-67/MIB1 immunohistochemistry warranted? If so, is there a preferred method to quantitate results?

LEVEL III: Ki67/MIB1 immunohistochemistry is recommended as an option for prognostic assessment.

Medical Subject Headings

Brain; Brain Neoplasms; Disease Management; Evidence-Based Medicine; Glioma; Humans; Neoplasm Grading

PubMed ID

26530263

Volume

125

Issue

3

First Page

531

Last Page

549

Find It @ Sladen

Share

COinS